particularly GlaxoSmithKline (GSK) and Boehringer Ingelheim (BI). In essence, people in South Africa living with HIV had to beg to live - by seeking donations and charity or pressuring their ...

South Africa has been part of a vaccine development programme, which is conducted by GlaxoSmithKline (GSK). “This gives us hope that indeed, we will end TB, by working with all role players, opinion ...

GSK has expanded a collaboration with BioVersys ... beyond a current phase 2a trial in pulmonary TB, which is ongoing in South Africa. The extension to the Series C takes the total raised by ...

GSK has upgraded its longstanding alliance ... that it has signed a non-binding memorandum of understanding with South Africa-based Afrigen Biologics to support the development of an mRNA vaccine ...

GSK will provide the adjuvant post-licensure if the trial is successful. The investigators aim to enroll up to 20,000 participants, including people living with HIV, at 60 trial sites in South Africa ...

Nigerians are bracing for more economic weakness after the local currency plunged to a record low against the US dollar. The ...

In 2007, BAE found itself subject to six investigations in the UK with regard to deals in Chile, the Czech Republic, Qatar, Romania, South Africa and Tanzania ... UK-based pharmaceuticals giant ...

Nigeria’s pharmaceutical companies are ramping up investments and expanding operations to tap growing local opportunities.

The company promoted by GSK Velu, who was an investor in diagnostic chain Metropolis ... with a presence not just in the Indian market but also in the UAE, US, and South Africa. The chain has the ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...